Status:

RECRUITING

Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock

Lead Sponsor:

Kingman Regional Medical Center

Collaborating Sponsors:

La Jolla Pharmaceutical Company

Conditions:

Septic Shock

Shock

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Norepinephrine is a catecholamine that is the first-line vasopressor for septic shock. The addition of non-catecholamine vasopressors, including vasopressin and angiotensin-II may be used in adults wi...

Detailed Description

Objectives: Primary Objective: 1\. To evaluate the efficacy of ang-II when used as the second vasopressor agent for septic shock Secondary Objectives: 1. To assess the duration of response to ang-...

Eligibility Criteria

Inclusion

  • Patients admitted to the ICU within 12 hours of presentation to the emergency department for septic shock requiring 15-25 mcg/min of norepinephrine. Septic shock will be defined as having a known or presumed infection with two or more criteria of systemic inflammatory response syndrome, a mean arterial pressure \<65 mm Hg despite fluid resuscitation requiring vasopressor support, and a serum lactate \>2 mmol/L. Criteria of systemic inflammatory response syndrome include a temperature \>100.4°F or \<96.8°F; heart rate \>90/min; respiratory rate \>20/min and a white blood cell count \>12,000/mm3 or \<4,000/mm3.

Exclusion

  • Age \<18 years
  • Pregnancy or lactation
  • Known allergic reactions to angiotensin-II or hydrocortisone sodium succinate
  • Requiring \>25 mcg/min of norepinephrine or on any vasopressor other than norepinephrine at study enrollment
  • Clinically significant bleeding precluding the use of chemical prophylaxis for venous thromboembolism
  • Treatment with another investigational drug or other intervention during study timeframe

Key Trial Info

Start Date :

December 4 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2025

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT06122987

Start Date

December 4 2023

End Date

January 1 2025

Last Update

May 23 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Kingman Regional Medical Center

Kingman, Arizona, United States, 86401

Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock | DecenTrialz